Emerging genes associated with the progression of nonalcoholic fatty liver disease
Christina Koutsari, Konstantinos N. Lazaridis – 26 August 2010
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease
Brent A. Neuschwander‐Tetri, Jeanne M. Clark, Nathan M. Bass, Mark L. Van Natta, Aynur Unalp‐Arida, James Tonascia, Claudia O. Zein, Elizabeth M. Brunt, David E. Kleiner, Arthur J. McCullough, Arun J. Sanyal, Anna Mae Diehl, Joel E. Lavine, Naga Chalasani, Kris V. Kowdley, NASH Clinical Research Network – 26 August 2010 – The Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) was formed to conduct multicenter studies on the etiology, contributing factors, natural history, and treatment of nonalcoholic steatohepatitis (NASH).
Transforming growth factor‐beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth
Serif Senturk, Mine Mumcuoglu, Ozge Gursoy‐Yuzugullu, Burcu Cingoz, Kamil Can Akcali, Mehmet Ozturk – 26 August 2010 – Senescence induction could be used as an effective treatment for hepatocellular carcinoma (HCC). However, major senescence inducers (p53 and p16Ink4a) are frequently inactivated in these cancers. We tested whether transforming growth factor‐β (TGF‐β) could serve as a potential senescence inducer in HCC. First, we screened for HCC cell lines with intact TGF‐β signaling that leads to small mothers against decapentaplegic (Smad)‐targeted gene activation.
PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease
Elizabeth K. Speliotes, Johannah L. Butler, Cameron D. Palmer, Benjamin F. Voight, the GIANT Consortium the MIGen Consortium, the NASH CRN, Joel N. Hirschhorn – 26 August 2010 – Single nucleotide polymorphisms (SNPs) near 7 loci have been associated with liver function tests or with liver steatosis by magnetic resonance spectroscopy. In this study we aim to test whether these SNPs influence the risk of histologically‐confirmed nonalcoholic fatty liver disease (NAFLD).
Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites
Thomas Sersté, Christian Melot, Claire Francoz, François Durand, Pierre‐Emmanuel Rautou, Dominique Valla, Richard Moreau, Didier Lebrec – 26 August 2010 – Beta‐blockers may have a negative impact on survival in patients with cirrhosis and refractory ascites. The aim of this study was to evaluate the effect of the administration of beta‐blockers on long‐term survival in patients with cirrhosis and refractory ascites.
The association of genetic variability in patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease
Yaron Rotman, Christopher Koh, Joseph M. Zmuda, David E. Kleiner, T. Jake Liang, the NASH CRN – 26 August 2010 – Genome‐wide association studies identified single‐nucleotide polymorphisms (SNPs) that are associated with increased hepatic fat or elevated liver enzymes, presumably reflecting nonalcoholic fatty liver disease (NAFLD).
Direct activation of forkhead box O3 by tumor suppressors p53 and p73 is disrupted during liver regeneration in mice
Svitlana Kurinna, Sabrina A. Stratton, Wen‐Wei Tsai, Kadir C. Akdemir, Weisong Gu, Pallavi Singh, Triona Goode, Gretchen J. Darlington, Michelle Craig Barton – 26 August 2010 – The p53 family of proteins regulates the expression of target genes that promote cell cycle arrest and apoptosis, which may be linked to cellular growth control as well as tumor suppression. Within the p53 family, p53 and the transactivating p73 isoform (TA‐p73) have hepatic‐specific functions in development and tumor suppression.
Twelve‐week posttreatment follow‐up predicts a sustained virological response to pegylated interferon and ribavirin therapy
Alessio Aghemo, Maria Grazia Rumi, Stella De Nicola, Massimo Colombo – 26 August 2010
Suppression of liver regeneration and hepatocyte proliferation in hepatocyte‐targeted glypican 3 transgenic mice
Bowen Liu, Aaron W. Bell, Shirish Paranjpe, William C. Bowen, Jaspal S. Khillan, Jian‐Hua Luo, Wendy M. Mars, George K. Michalopoulos – 26 August 2010 – Glypican 3 (GPC3) belongs to a family of glycosylphosphatidylinositol‐anchored, cell‐surface heparan sulfate proteoglycans. GPC3 is overexpressed in hepatocellular carcinoma. Loss‐of‐function mutations of GPC3 result in Simpson‐Golabi‐Behmel syndrome, an X‐linked disorder characterized by overgrowth of multiple organs, including the liver.
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration
Fatima Teixeira‐Clerc, Marie‐Pierre Belot, Sylvie Manin, Vanessa Deveaux, Thomas Cadoudal, Marie‐Noele Chobert, Alexandre Louvet, Andreas Zimmer, Thierry Tordjmann, Ariane Mallat, Sophie Lotersztajn – 26 August 2010 – The cannabinoid receptor 2 (CB2) plays a pleiotropic role in innate immunity and is a crucial mediator of liver disease. In this study, we investigated the impact of CB2 receptors on the regenerative process associated with liver injury.